Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis

Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis

Yuya Seko,1 Taichiro Nishikawa,1 Atsushi Umemura,1 Kanji Yamaguchi,1 Michihisa Moriguchi,1 Kohichiroh Yasui,1 Mayumi Kimura,2 Hiroaki Iijima,3 Toshio Hashimoto,3 Yoshio Sumida,4 Takeshi Okanoue,5 Yoshito Itoh1 1Department of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine,...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Seko Y, Nishikawa T, Umemura A, Yamaguchi K, Moriguchi M, Yasui K, Kimura M, Iijima H, Hashimoto T, Sumida Y, Okanoue T, Itoh Y
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2018
Materias:
canagliflozin
Japanese
NASH
fibrosis stages
SGLT2 inhibitor
type 2 diabetes mellitus
Specialties of internal medicine
RC581-951
Acceso en línea:https://doaj.org/article/bfba1e10d95f4001b5ead934038fdfe6
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/bfba1e10d95f4001b5ead934038fdfe6

Ejemplares similares